Literature DB >> 2563098

Lone bilateral blindness: a transient ischaemic attack.

M S Dennis1, J M Bamford, P A Sandercock, C P Warlow.   

Abstract

In the Oxfordshire Community Stroke Project 14 patients were notified with lone bilateral blindness, defined as rapid onset of dimming or loss of vision over all of both visual fields simultaneously, lasting under 24 hours, without associated symptoms of focal cerebral ischaemia, epilepsy, or reduction in consciousness. The age of these patients was close to that of the 184 patients who presented with transient ischaemic attacks and they had a similar high prevalence of vascular risk factors. During a mean follow-up of 2.4 years, 5 of the 14 had a first-ever stroke (0.31 expected). In view of their 16 times (95% CI 7-39 times) excess risk of stroke such patients should be included, for practical purposes, under the diagnostic heading of transient ischaemic attack.

Entities:  

Mesh:

Year:  1989        PMID: 2563098     DOI: 10.1016/s0140-6736(89)91203-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  4 in total

1.  TIA--treacherously inaccurate acronym.

Authors:  Herbert L Fred
Journal:  Tex Heart Inst J       Date:  2002

2.  Long-term prognosis of transient lone bilateral blindness in adolescents and young adults.

Authors:  S Bower; M Dennis; C Warlow; N Jordan; H Sagar
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-06       Impact factor: 10.154

3.  Diagnosis of non-consensus transient ischaemic attacks with focal, negative, and non-progressive symptoms: population-based validation by investigation and prognosis.

Authors:  Maria A Tuna; Peter M Rothwell
Journal:  Lancet       Date:  2021-03-06       Impact factor: 79.321

4.  Non-focal neurological symptoms associated with classical presentations of transient ischaemic attack: qualitative analysis of interviews with patients.

Authors:  Susan Kirkpatrick; Louise Locock; Matthew F Giles; Daniel S Lasserson
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.